Drugs / AZD6793
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07433062 | Jan → Jun 2026 | type 2 diabetes mellitus | AstraZeneca | Suspended | No outcome recorded |
| Phase 1 | NCT06494644 | Jul → Oct 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06368440 | May → Dec 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05662033 | Dec 2022 → Oct 2024 | inflammatory disease | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07082738 | Jun 2025 → Nov 2027 expected | chronic obstructive pulmonary disease | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6793 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06368440 ↗ |
| Route | Oral | “AZD6793 will be administered orally” NCT05662033 ↗ |